Difference between revisions of "Example orders for R-CHOP in lymphoma"
Warner-admin (talk | contribs) m (Text replacement - "Just 9 days left" to "Just 8 days left") |
m (Text replacement - "{|style="width: 100%; border-left:solid 20px #dc143c;border-right:solid 20px #dc143c;border-top:solid 20px #dc143c;border-bottom:solid 20px #dc143c;" align="center" | <span style="font-family:Arial; font-size:300%"> Just 8 days left to fill out a survey on how we can make HemOnc.org better and more useful.<br> '''Link:''' http://j.mp/2BlBaoQ </span> |}" to "{{:Editing test page 2}}") |
||
Line 1: | Line 1: | ||
− | { | + | {{:Editing test page 2}}<br>'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].''' |
− | |||
− | |||
− | |||
− | |||
− | |||
Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature. | Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature. |
Revision as of 13:07, 25 January 2018
Carboplatin & Paclitaxel (CP)
CP: Carboplatin & Paclitaxel
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Forde et al. 2022 (CheckMate 816) | 2017-2019 | Phase 3 (C) | 1a. CP & Nivolumab 1b. CVb & Nivolumab 1c. DC & Nivolumab |
Inferior EFS |
Note: there were additional comparator options depending on histology; see the respective histology-specific pages for more details. This study was conducted in the United States. The reason for the study was that an unanswered question at the time was whether adding an immune checkpoint inhibitor would improve outcomes.
Biomarker eligibility criteria
- CheckMate 816: No sensitizing EGFR or ALK mutations
Chemotherapy
- Carboplatin (Paraplatin) AUC 5 or 6 IV once on day 1
- Paclitaxel (Taxol) 175 or 200 mg/m2 IV once on day 1
21-day cycle for 3 cycles
Subsequent treatment
References
- CheckMate 816: Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N; CheckMate 816 Investigators. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022 May 26;386(21):1973-1985. Epub 2022 Apr 11. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT02998528
Start of hidden/commented information for virtual editor End of hidden/commented information for virtual editor
Start of comment inserted by visual editor(edited again by visual editor)
(edited again by visual editor end)End of comment inserted by visual editor
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If this is your first time visiting, we suggest you read the tutorial.
Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature.
R-CHOP
R-CHOP: Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone
Original references may be found at R-CHOP (Non-Hodgkin lymphoma)
Example regimen #1
- Cyclophosphamide (Cytoxan) 750 mg/m2 IV on day 1
- Infuse over 30 to 45 minutes.
- Doxorubicin (Adriamycin) 50 mg/m2 IV on day 1
- Administer IV push through running IV.
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2mg per cycle) IV on day 1
- Administer IV push through running IV. Make sure to address patient's bowel status.
- Prednisone (Sterapred) 100 mg PO once per day on days 1 to 5
- Rituximab (Rituxan) 375 mg/m2 IV on day 1
- Infusion rate per hospital policy.
21-day cycles x 6 cycles
Supportive medications
- Pegfilgrastim (Neulasta) 6 mg SC x1 on day 3
- Acetaminophen (Tylenol) 650 mg PO 30 to 60 minutes prior to Rituximab (Rituxan)
- Diphenhydramine (Benadryl) 25 to 50 mg PO/IV 30 to 60 minutes prior to Rituximab (Rituxan). 50 mg to be used for the first dose of Rituximab (Rituxan). Dose may be reduced to 25 mg on subsequent Rituximab (Rituxan) treatments if tolerated.
- Ondansetron (Zofran) 8 mg IV 30 minutes prior to CHOP
- Hydrocortisone (Cortef) 50 mg IV prn Rituximab (Rituxan) infusion reaction, may repeat x1
Hydration:
- Prehydration with 500 ml NS at 500 mL/hour, to start 60 minutes before chemotherapy
- 500 ml NS at KVO rate to be used as running IV for chemotherapy infusion. Give up to 500 ml NS.
Monitoring:
- On day 1 of each cycle: CBC with differential, absolute neutrophil count (ANC), BUN/Cr as part of a comprehensive metabolic panel, alk phos, AST, ALT, total bilirubin, albumin, LDH
- Physician to be notified if liver function tests or bilirubin are not within normal limits
- On day 8, check nadir CBC with differential, absolute neutrophil count (ANC). Need for further nadir count checks to be determined by degree of cytopenias.
- Check hepatitis B status prior to therapy with rituximab
Outpatient medications:
- Prednisone (Sterapred) as described above
- Ondansetron (Zofran) 8 mg PO Q8H prn nausea
- Acyclovir (Zovirax) 400 mg PO Q8H
- Allopurinol (Zyloprim) 100 to 300 mg PO once per day, adjusted for renal function
Clinical scenario & comments:
- 74 year-old gentleman with diffuse large B-cell lymphoma (DLBCL), using R-CHOP as first-line therapy. This patient had a creatinine of 1.4, with calculated creatinine clearance by Cockcroft-Gault of 55, but the team chose to be more conservative with allopurinol dosing and used 100 mg PO daily.